2022
Percutaneous Coronary Intervention vs. Coronary Artery Bypass Grafting for Treating In-Stent Restenosis in Unprotected-Left Main: LM-DRAGON-Registry
Wańha W, Bil J, Kołodziejczak M, Kowalówka A, Kowalewski M, Hudziak D, Gocoł R, Januszek R, Figatowski T, Milewski M, Tomasiewicz B, Kübler P, Hrymniak B, Desperak P, Kuźma Ł, Milewski K, Góra B, Łoś A, Kulczycki J, Włodarczak A, Skorupski W, Grygier M, Lesiak M, D'Ascenzo F, Andres M, Kleczynski P, Litwinowicz R, Borin A, Smolka G, Reczuch K, Gruchała M, Gil RJ, Jaguszewski M, Bartuś K, Suwalski P, Dobrzycki S, Dudek D, Bartuś S, Ga̧sior M, Ochała A, Lansky AJ, Deja M, Legutko J, Kedhi E, Wojakowski W. Percutaneous Coronary Intervention vs. Coronary Artery Bypass Grafting for Treating In-Stent Restenosis in Unprotected-Left Main: LM-DRAGON-Registry. Frontiers In Cardiovascular Medicine 2022, 9: 849971. PMID: 35615559, PMCID: PMC9125786, DOI: 10.3389/fcvm.2022.849971.Peer-Reviewed Original ResearchPercutaneous coronary interventionTarget vessel revascularizationCoronary artery bypassCardiac deathMyocardial infarctionPCI groupArtery bypassCoronary interventionStent restenosisUnprotected left main coronary arteryLeft main coronary arteryMain coronary arteryManagement of patientsAnalysis of patientsCerebrovascular eventsPrimary endpointVessel revascularizationConsecutive patientsCoronary arteryCABGLower incidenceLower riskPatientsDeathMACCE
2021
Long term outcomes of ultrathin versus standard thickness second‐generation drug eluting stents: Meta‐analysis of randomized trials
Hussain Y, Gaston S, Kluger J, Shah T, Yang Y, Tirziu D, Lansky A. Long term outcomes of ultrathin versus standard thickness second‐generation drug eluting stents: Meta‐analysis of randomized trials. Catheterization And Cardiovascular Interventions 2021, 99: 563-574. PMID: 34236755, DOI: 10.1002/ccd.29866.Peer-Reviewed Original ResearchConceptsSecond generation drug eluting stentsTarget lesion failureDrug eluting stentsLong-term outcomesEluting stentsTerm outcomesRisk ratioIschemia-driven target vessel revascularizationTarget vessel myocardial infarctionLong-term clinical outcomesProbable stent thrombosisTarget vessel revascularizationTerm clinical outcomesVessel myocardial infarctionPercutaneous coronary interventionCoronary artery diseaseConfidence intervalsFirst generation drug eluting stentsRandom-effects modelLesion failureVessel revascularizationCoronary interventionSecondary outcomesArtery diseaseCardiac death
2020
Long‐term serial functional evaluation after implantation of the Fantom sirolimus‐eluting bioresorbable coronary scaffold
Saito Y, Cristea E, Bouras G, Abizaid A, Lutz M, Carrié D, Weber‐Albers J, Dudek D, Anderson J, Lansky A, Investigators T. Long‐term serial functional evaluation after implantation of the Fantom sirolimus‐eluting bioresorbable coronary scaffold. Catheterization And Cardiovascular Interventions 2020, 97: 431-436. PMID: 32077590, DOI: 10.1002/ccd.28804.Peer-Reviewed Original ResearchConceptsPost-percutaneous coronary interventionQuantitative flow ratioBioresorbable coronary scaffoldTarget vessel revascularizationVessel revascularizationFunctional ischemiaStable coronary artery diseaseTime of revascularizationCoronary artery diseaseFractional flow reserveQFR assessmentII trialAngiographic outcomesCoronary interventionUnstable anginaArtery diseaseQFR valueWire-based fractional flow reserveSignificant lesionsFlow reservePatientsTarget vesselRevascularizationQFR analysisFunctional evaluation
2015
Pretreatment with aspirin in acute coronary syndromes: Lessons from the ACUITY and HORIZONS-AMI trials
Brener SJ, Mehran R, Lansky AJ, Ayele GM, Stone GW. Pretreatment with aspirin in acute coronary syndromes: Lessons from the ACUITY and HORIZONS-AMI trials. European Heart Journal Acute Cardiovascular Care 2015, 5: 449-454. PMID: 26722003, DOI: 10.1177/2048872615624848.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeHORIZONS-AMI trialCoronary syndromeAspirin pretreatmentMyocardial infarctionCardiac deathStent thrombosisSegment elevation acute coronary syndromesST-segment elevation myocardial infarctionElevation acute coronary syndromeAcute coronary syndrome patientsLarge randomized clinical trialsAdverse ischemic eventsTarget vessel revascularizationCoronary syndrome patientsIndependent risk factorElevation myocardial infarctionLarge prospective studiesHigh-risk cohortIncidence of deathRandomized clinical trialsMultivariable regression analysisPrior revascularizationVessel revascularizationIschemic events
2014
Short and long-term safety and efficacy of polymer-free vs. durable polymer drug-eluting stents. A comprehensive meta-analysis of randomized trials including 6178 patients
Navarese EP, Kowalewski M, Cortese B, Kandzari D, Dias S, Wojakowski W, Buffon A, Lansky A, Angelini P, Torguson R, Kubica J, Kelm M, de Boer MJ, Waksman R, Suryapranata H. Short and long-term safety and efficacy of polymer-free vs. durable polymer drug-eluting stents. A comprehensive meta-analysis of randomized trials including 6178 patients. Atherosclerosis 2014, 233: 224-231. PMID: 24529148, DOI: 10.1016/j.atherosclerosis.2013.12.024.Peer-Reviewed Original ResearchConceptsDurable polymer drug-eluting stentsDrug-eluting stentsStent thrombosisPolymer-free drug-eluting stentsRandomized trialsMyocardial infarctionMain efficacy endpointLong-term safetyLesion revascularizationEfficacy endpointSafety endpointVessel revascularizationMI ratesLong followCochrane DatabaseSafety profileClinical practiceRCTsGoogle ScholarConflicting resultsRevascularizationSignificant differencesEfficacyPatientsEndpoint
2013
Relationship Between ST-Segment Recovery and Clinical Outcomes After Primary Percutaneous Coronary Intervention
Farkouh ME, Reiffel J, Dressler O, Nikolsky E, Parise H, Cristea E, Baran DA, Dizon J, Merab JP, Lansky AJ, Mehran R, Stone GW. Relationship Between ST-Segment Recovery and Clinical Outcomes After Primary Percutaneous Coronary Intervention. Circulation Cardiovascular Interventions 2013, 6: 216-223. PMID: 23652600, DOI: 10.1161/circinterventions.112.000142.Peer-Reviewed Original ResearchMeSH KeywordsAgedChi-Square DistributionCoronary AngiographyElectrocardiographyFemaleFibrinolytic AgentsHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsProportional Hazards ModelsRecovery of FunctionRisk FactorsStentsTime FactorsTreatment OutcomeConceptsPrimary percutaneous coronary interventionST-segment elevation myocardial infarctionPrimary PCIMajor adverse cardiovascular eventsST-segment resolutionAdverse cardiovascular eventsIschemia-driven target vessel revascularizationComplete ST-segment resolutionTarget vessel revascularizationPercutaneous coronary interventionMyocardial infarctionCardiovascular eventsVessel revascularizationCoronary interventionIndependent predictorsDegree of STRBaseline ST-segment elevationAcute Myocardial Infarction trialLong-term prognostic valueLong-term cardiovascular mortalityLeft ventricular ejection fractionLong-term predictive valuePost-PCI electrocardiogramsMyocardial infarction (TIMI) flowMyocardial Infarction trial
2012
Comparison of clinical and angiographic prognostic risk scores in patients with acute coronary syndromes: Analysis from the Acute Catheterization and Urgent Intervention Triage StrategY (ACUITY) trial
Palmerini T, Caixeta A, Genereux P, Cristea E, Lansky A, Mehran R, Dangas G, Lazar D, Sanchez R, Fahy M, Xu K, Stone GW. Comparison of clinical and angiographic prognostic risk scores in patients with acute coronary syndromes: Analysis from the Acute Catheterization and Urgent Intervention Triage StrategY (ACUITY) trial. American Heart Journal 2012, 163: 383-391.e5. PMID: 22424008, DOI: 10.1016/j.ahj.2011.11.010.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionCardiac Surgery (SYNTAX) scoreNet reclassification improvementAcute coronary syndromePrognostic risk scoreMyocardial infarctionRisk scoreAngiographic variablesVessel revascularizationCardiac mortalityCoronary syndromeEnd pointSurgery scoreSegment elevation acute coronary syndromesUrgent Intervention Triage Strategy (ACUITY) trialAcute Coronary Events (GRACE) scoreElevation acute coronary syndromeNew risk stratification scoreEjection fraction (ACEF) scoreIschemic end pointsMyocardial Infarction (TIMI) scoreTarget vessel revascularizationRisk stratification scoresCoronary artery diseaseMost end points
2010
The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention.
Saltzman AJ, Mehran R, Hooper WC, Moses JW, Weisz G, Collins MB, Lansky AJ, Kreps EM, Leon MB, Stone GW, Dangas G. The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention. Journal Of Invasive Cardiology 2010, 22: 2-6. PMID: 20048389.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngina, UnstableAngioplasty, Balloon, CoronaryAntibodies, MonoclonalBlood PlateletsC-Reactive ProteinDose-Response Relationship, DrugDouble-Blind MethodDrug Therapy, CombinationFemaleHeparinHumansImmunoglobulin Fab FragmentsMaleMiddle AgedPilot ProjectsPlatelet AggregationPlatelet Aggregation InhibitorsStentsTime FactorsTirofibanTyrosineConceptsPercutaneous coronary interventionC-reactive proteinTarget vessel revascularizationPlatelet inhibitionCoronary interventionLevels of CRPInflammatory markers C-reactive proteinPlatelet aggregationC-reactive protein levelsDouble-blind study designEfficacy of tirofibanLower platelet inhibitionCoronary artery bypassCoronary artery revascularizationArtery revascularizationDiabetic subsetEligible patientsNonfatal MIArtery bypassHs-CRPVessel revascularizationSpearman correlation coefficient modelClinical endpointsFirst time pointTirofiban
2009
5-Year Clinical Outcomes After Sirolimus-Eluting Stent Implantation Insights From a Patient-Level Pooled Analysis of 4 Randomized Trials Comparing Sirolimus-Eluting Stents With Bare-Metal Stents
Caixeta A, Leon MB, Lansky AJ, Nikolsky E, Aoki J, Moses JW, Schofer J, Morice MC, Schampaert E, Kirtane AJ, Popma JJ, Parise H, Fahy M, Mehran R. 5-Year Clinical Outcomes After Sirolimus-Eluting Stent Implantation Insights From a Patient-Level Pooled Analysis of 4 Randomized Trials Comparing Sirolimus-Eluting Stents With Bare-Metal Stents. Journal Of The American College Of Cardiology 2009, 54: 894-902. PMID: 19712798, DOI: 10.1016/j.jacc.2009.04.077.Peer-Reviewed Original ResearchConceptsBare metal stentsTarget vessel revascularizationStent thrombosisRate of deathMyocardial infarctionVessel revascularizationPooled analysisAcademic Research Consortium definitionsPatient-level pooled analysisDrug-eluting stent implantationArterial healing responseComposite of deathProbable stent thrombosisLong-term safetyDrug-eluting stentsLate stent thrombosisClinical outcomesRandomized trialsStent implantationSuperior efficacyBMS groupThrombosisHealing responseSES groupStentsImpact of Thienopyridine Administration Prior to Primary Stenting in Acute Myocardial Infarction
RABBANI LE, IYENGAR S, DANGAS GD, GRINES CL, COX DA, GARCIA E, TCHENG JE, GRIFFIN JJ, GUAGLIUMI G, STUCKEY T, TURCO M, STANT J, FAHY M, LANSKY AJ, MEHRAN R, STONE GW. Impact of Thienopyridine Administration Prior to Primary Stenting in Acute Myocardial Infarction. Journal Of Interventional Cardiology 2009, 22: 378-384. PMID: 19496901, DOI: 10.1111/j.1540-8183.2009.00474.x.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAspirinConfidence IntervalsDrug Therapy, CombinationDrug-Eluting StentsFemaleHumansImmunoglobulin Fab FragmentsKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial RevascularizationOdds RatioPlatelet Aggregation InhibitorsPreoperative CarePyridinesTime FactorsConceptsMajor adverse cardiovascular eventsAcute myocardial infarctionTarget vessel revascularizationIschemic target vessel revascularizationPrimary stentingThienopyridine administrationLoading doseTH patientsStent implantationMyocardial infarctionClopidogrel loading doseAdverse cardiovascular eventsSuperior clinical outcomesBare-metal stentingAbciximab useCADILLAC trialCardiovascular eventsVessel revascularizationClinical outcomesMetal stentingProcedural characteristicsOperator's discretionPatientsStentingCore labSafety and Efficacy of Drug-Eluting and Bare Metal Stents
Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, Brodie B, Hannan E, Harjai K, Jensen LO, Park SJ, Perry R, Racz M, Saia F, Tu JV, Waksman R, Lansky AJ, Mehran R, Stone GW. Safety and Efficacy of Drug-Eluting and Bare Metal Stents. Circulation 2009, 119: 3198-3206. PMID: 19528338, DOI: 10.1161/circulationaha.108.826479.Peer-Reviewed Original ResearchConceptsBare metal stentsDrug-eluting stentsTarget vessel revascularizationMyocardial infarctionVessel revascularizationObservational studyMetal stentsEfficacy end pointTotal patientsOverall mortalityDrug-ElutingDES useLabel indicationsLabel useResidual confoundingBMS useRCTsPatientsDrug AdministrationInfarctionRevascularizationEnd pointMortality dataComparable reductionStents
2008
Clinical and angiographic outcomes in diabetic patients following single or multivessel stenting in the COSTAR II randomized trial.
Kereiakes DJ, Petersen JL, Batchelor WB, Fitzgerald PJ, Mehran R, Lansky A, Tsujino I, Schofer J, Dubois C, Verheye S, Cristea E, Garg J, Wijns W, Krucoff MW. Clinical and angiographic outcomes in diabetic patients following single or multivessel stenting in the COSTAR II randomized trial. Journal Of Invasive Cardiology 2008, 20: 335-41. PMID: 18599890.Peer-Reviewed Original ResearchMeSH KeywordsAngiographyAngioplasty, Balloon, CoronaryBlood GlucoseCoronary Artery DiseaseDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Drug-Eluting StentsFemaleFollow-Up StudiesGlycated HemoglobinHumansMaleMiddle AgedProspective StudiesRetrospective StudiesSingle-Blind MethodStentsTreatment OutcomeConceptsMajor adverse cardiovascular eventsPercutaneous coronary interventionDiabetic patientsAngiographic outcomesAdverse outcomesTaxus stentStent deploymentBare metal stent deploymentAdverse cardiovascular eventsMultivessel coronary diseaseTarget vessel revascularizationImproved clinical outcomesAngiographic restenosisCardiovascular eventsVessel revascularizationCoronary interventionCoronary diseaseGlycemic controlMultivessel stentingClinical outcomesDiabetic cohortElevated HbA1cLate lumenPatientsDiabetesA Novel Bioresorbable Polymer Paclitaxel-Eluting Stent for the Treatment of Single and Multivessel Coronary Disease Primary Results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II Study
Krucoff MW, Kereiakes DJ, Petersen JL, Mehran R, Hasselblad V, Lansky AJ, Fitzgerald PJ, Garg J, Turco MA, Simonton CA, Verheye S, Dubois CL, Gammon R, Batchelor WB, O'Shaughnessy CD, Hermiller JB, Schofer J, Buchbinder M, Wijns W, Group C. A Novel Bioresorbable Polymer Paclitaxel-Eluting Stent for the Treatment of Single and Multivessel Coronary Disease Primary Results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II Study. Journal Of The American College Of Cardiology 2008, 51: 1543-1552. PMID: 18420096, DOI: 10.1016/j.jacc.2008.01.020.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAngioplasty, Balloon, CoronaryAntineoplastic Agents, PhytogenicChromium AlloysClopidogrelCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisDiabetes MellitusFemaleHumansMaleMiddle AgedPaclitaxelPlatelet Aggregation InhibitorsPolymersRiskThromboembolismTiclopidineTime FactorsConceptsPercutaneous coronary interventionTarget vessel revascularizationDrug-eluting stentsMajor adverse cardiac eventsMultivessel percutaneous coronary interventionTaxus drug-eluting stentsMyocardial infarctionAdjudicated deathAdverse cardiac eventsPrimary end pointSegment late lossSingle target lesionPre-specified subgroupsStent thrombosis ratesTreatment of SingleVessel revascularizationCardiac eventsCoronary interventionII studyThrombosis rateAngiographic analysisEpicardial vesselsTarget lesionsLate lossPatients
2007
Clinical Outcomes After Heterogeneous Overlap Stenting With Drug-Eluting Stents and Bare-Metal Stents for de Novo Coronary Artery Narrowings
Aoki J, Kirtane AJ, Dangas GD, Lansky AJ, Morales A, Kimura M, Kim YH, Moussa I, Weisz G, Kreps EM, Collins M, Frankin-Bond T, Stone GW, Moses JW, Leon MB, Mehran R. Clinical Outcomes After Heterogeneous Overlap Stenting With Drug-Eluting Stents and Bare-Metal Stents for de Novo Coronary Artery Narrowings. The American Journal Of Cardiology 2007, 101: 58-62. PMID: 18157966, DOI: 10.1016/j.amjcard.2007.07.049.Peer-Reviewed Original ResearchConceptsDrug-eluting stentsBare metal stentsClinical outcomesTarget vessel revascularization rateMultiple drug-eluting stentsAcute stent thrombosisVessel revascularization rateDe novo lesionsTarget vessel revascularizationPercutaneous coronary interventionCoronary artery narrowingImplanted stent diameterNovo lesionsProspective registryRevascularization ratesVessel revascularizationBMS implantationCoronary interventionDES implantationConsecutive patientsArtery narrowingStent thrombosisMyocardial infarctionStent restenosisStent diameterShort- and Long-Term Outcomes After Stent-Assisted Percutaneous Treatment of Saphenous Vein Grafts in the Drug-Eluting Stent Era
Pucelikova T, Mehran R, Kirtane AJ, Kim YH, Fahy M, Weisz G, Lansky AJ, Moussa I, Gray WA, Collins MB, Kodali SK, Stone GW, Moses JW, Leon MB, Dangas G. Short- and Long-Term Outcomes After Stent-Assisted Percutaneous Treatment of Saphenous Vein Grafts in the Drug-Eluting Stent Era. The American Journal Of Cardiology 2007, 101: 63-68. PMID: 18157967, DOI: 10.1016/j.amjcard.2007.07.048.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCoronary AngiographyCoronary Artery BypassFemaleFollow-Up StudiesGraft Occlusion, VascularHumansMaleMultivariate AnalysisMyocardial InfarctionMyocardiumNecrosisPaclitaxelProspective StudiesProsthesis DesignRegistriesRetreatmentSaphenous VeinSirolimusStentsThrombosisConceptsMajor adverse cardiac eventsAdverse cardiac eventsPercutaneous coronary interventionDrug-eluting stentsSVG lesionsVessel revascularizationCardiac eventsCoronary interventionPercutaneous treatmentMyocardial infarctionStent-assisted percutaneous coronary interventionSaphenous vein graft lesionsNative vessel diseasePeriprocedural myocardial necrosisTarget lesion revascularizationTarget vessel revascularizationSaphenous vein graftsVein graft lesionsPresence of thrombusEmbolic protection devicesHigh-risk subgroupsLong-term outcomesContemporary clinical practiceLesion revascularizationStent thrombosesGender-Specific Outcomes After Sirolimus-Eluting Stent Implantation
Solinas E, Nikolsky E, Lansky AJ, Kirtane AJ, Morice MC, Popma JJ, Schofer J, Schampaert E, Pucelikova T, Aoki J, Fahy M, Dangas GD, Moses JW, Cutlip DE, Leon MB, Mehran R. Gender-Specific Outcomes After Sirolimus-Eluting Stent Implantation. Journal Of The American College Of Cardiology 2007, 50: 2111-2116. PMID: 18036446, DOI: 10.1016/j.jacc.2007.06.056.Peer-Reviewed Original ResearchConceptsSirolimus-eluting stentsBare metal stentsSegment binary restenosisBinary restenosisClinical outcomesMajor adverse cardiac eventsSirolimus-Eluting Stent ImplantationAdverse cardiac eventsOutcomes of patientsTarget vessel revascularizationCongestive heart failureOutcomes of womenPercutaneous coronary interventionOverall clinical outcomeGender-specific differencesVessel revascularizationCardiac eventsCoronary interventionAngiographic featuresDiabetes mellitusHeart failureIndependent predictorsMultivariable analysisClinical benefitStent implantation
2006
Comparative Early and Late Outcomes After Primary Percutaneous Coronary Intervention in ST-Segment Elevation and Non–ST-Segment Elevation Acute Myocardial Infarction (from the CADILLAC Trial)
Cox DA, Stone GW, Grines CL, Stuckey T, Zimetbaum PJ, Tcheng JE, Turco M, Garcia E, Guagliumi G, Iwaoka RS, Mehran R, O’Neill W, Lansky AJ, Griffin JJ, Investigators C. Comparative Early and Late Outcomes After Primary Percutaneous Coronary Intervention in ST-Segment Elevation and Non–ST-Segment Elevation Acute Myocardial Infarction (from the CADILLAC Trial). The American Journal Of Cardiology 2006, 98: 331-337. PMID: 16860018, DOI: 10.1016/j.amjcard.2006.01.102.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAnticoagulantsBlood Vessel Prosthesis ImplantationCoated Materials, BiocompatibleElectrocardiographyFemaleFollow-Up StudiesHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMyocardial InfarctionPlatelet Glycoprotein GPIIb-IIIa ComplexStentsStroke VolumeSurvival RateTime FactorsTreatment OutcomeConceptsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionPrimary PCIMyocardial Infarction (TIMI) grade 3 flowIschemic target vessel revascularizationGrade 3 flowOutcomes of patientsTarget vessel revascularizationPercutaneous coronary interventionVessel revascularizationAcute MICoronary interventionMyocardial infarctionAcute ST-segment elevation myocardial infarctionSegment elevation acute myocardial infarctionMajor adverse cardiac eventsElevation acute myocardial infarctionOngoing chest painSimilar late mortalityAdverse cardiac eventsElevation myocardial infarctionST-segment elevationAcute myocardial infarctionHigher ejection fractionPostprocedural ThrombolysisDrug-Eluting Stents in the Treatment of Intermediate Lesions Pooled Analysis From Four Randomized Trials
Moses JW, Stone GW, Nikolsky E, Mintz GS, Dangas G, Grube E, Ellis SG, Lansky AJ, Weisz G, Fahy M, Na Y, Russell ME, Donohoe D, Leon MB, Mehran R. Drug-Eluting Stents in the Treatment of Intermediate Lesions Pooled Analysis From Four Randomized Trials. Journal Of The American College Of Cardiology 2006, 47: 2164-2171. PMID: 16750680, DOI: 10.1016/j.jacc.2006.01.068.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsDrug-eluting stentsTarget vessel revascularizationIntermediate lesionsAngiographic restenosisMyocardial infarctionCardiac deathStent thrombosisDe novo coronary artery lesionsIntroduction of DESLate major adverse cardiac eventsEfficacy of DESNovo coronary artery lesionsBinary angiographic restenosisAdverse cardiac eventsCoronary artery lesionsCurrent treatment paradigmsTreatment of patientsIntermediate coronary lesionsBalloon-expandable stentsLower ratesEverolimus trialsRestenosis reductionTAXUS IVVessel revascularizationA multicenter, randomized, dose-finding study of gamma intracoronary radiation therapy to inhibit recurrent restenosis after stenting.
Price MJ, Moses JW, Leon MB, Mehran R, Negoita M, Lansky A, Collins M, Giap H, Lin R, Jani S, Steuterman S, Balter S, Dalton J, Lipsztein R, Tripuraneni P, Teirstein PS. A multicenter, randomized, dose-finding study of gamma intracoronary radiation therapy to inhibit recurrent restenosis after stenting. Journal Of Invasive Cardiology 2006, 18: 169-73. PMID: 16732060.Peer-Reviewed Original ResearchConceptsIntracoronary radiation therapyStent restenosisRadiation therapyLesion late lossTarget lesion revascularizationHigh-dose groupDose-finding studySignificant clinical problemBare metal stentsRadiation dose prescriptionHigh radiation doseBinary restenosisLesion revascularizationRecurrent restenosisVessel revascularizationAdverse eventsCoronary interventionRecurrent stenosisComposite endpointRandomized studyDose groupClinical eventsMyocardial infarctionRadiation failureGy group
2005
Two-year clinical follow-up of 90Sr/90 Y β-radiation versus placebo control for the treatment of in-stent restenosis
Silber S, Popma JJ, Suntharalingam M, Lansky AJ, Heuser RR, Speiser B, Teirstein PS, Bass T, O'Neill W, Lasala J, Reisman M, Sharma SK, Kuntz RE, Bonan R, Investigators F. Two-year clinical follow-up of 90Sr/90 Y β-radiation versus placebo control for the treatment of in-stent restenosis. American Heart Journal 2005, 149: 689-694. PMID: 15990754, DOI: 10.1016/j.ahj.2004.05.061.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAnticoagulantsBeta ParticlesBrachytherapyCoronary AngiographyCoronary DiseaseCoronary RestenosisDiabetes ComplicationsDisease-Free SurvivalFemaleFollow-Up StudiesHumansLife TablesMaleMiddle AgedPrognosisStentsStrontium RadioisotopesThrombophiliaTreatment OutcomeYttrium RadioisotopesConceptsMajor adverse cardiac eventsTarget vessel revascularizationStent restenosisIntracoronary brachytherapyOriginal patientsPrimary safety end pointTwo-year clinical outcomesPlacebo-controlled randomized trialEnd pointAdverse cardiac eventsPlacebo-controlled studyPrimary end pointSafety end pointKaplan-Meier analysisInitial beneficial effectsRestenosis TrialVessel revascularizationCardiac eventsPlacebo armClinical followActive treatmentClinical outcomesRandomized trialsPlacebo controlPatients